INTRODUCTION
Regulation of phospholipase D (PLD) activity in animal cells has recently received considerable attention because phospholipid hydrolysis by this enzyme produces phosphatidic acid, a potential second messenger in several cell types [1] [2] [3] [4] [5] [6] . It is generally accepted that protein kinase C (PKC) is a major regulator of PLD (reviewed in [7, 8] ); however, the mechanism(s) by which such regulation occur(s) is(are) not known. Most cell types contain several PKC isoenzymes, which may have specific functions [9] . Identification of the PKC isoenzyme(s) involved in the regulation of PLD activity is an important step in understanding the regulatory mechanism itself. Recently, Eldar et al. [10] reported that overexpression of PKC-a in fibroblasts failed to alter regulation of PLD by the PKC activator phorbol 12-myristate 13-acetate (PMA). They concluded that PKC-a is not a direct regulator of PLD and suggested, instead, that PKC-e may have such regulatory function. In apparent agreement with this possibility, most recently Pfeilschifter and Huwiler [11] reported that after 8 h treatment of rat renal mesangial cells with PMA, PLD still was fully active, despite complete downregulation of PKC-a and PKC-8, but not PKC-e. On the basis of these findings, they concluded that PLD activity was regulated by PKC-e [11] .
In a previous study [12] , we reported that 15 -fold overexpression of PKC-e in NIH 3T3 fibroblasts promoted the stimulatory effect of ethanol on phospholipase C-mediated hydrolysis of phosphatidylethanolamine (PtdEtn). However, subsequently we observed that PMA-induced PLD-mediated hydrolysis of PtdEtn and phosphatidylcholine (PtdCho) in PKCe overexpressors was increased only about 1.5-fold, regardless of appeared to promote slightly PMA-induced membrane translocation of the cytosolic forms of these isoenzymes in exponentially growing cells. Carcinogens and/or PMA had no effects on the cellular content or distribution of PKC-a. Chronic (24 h) treatments with carcinogens resulted in increased or decreased release of ['4C]ethanolamine or ['4C ]choline from the appropriate prelabelled phospholipids, respectively. However, carcinogens failed to block the stimulatory effects of PMA and PDGF on the hydrolysis of phosphatidylethanolamine and phosphatidylcholine or on the synthesis of phosphatidylethanol mediated by PLD. These data indicate that in fibroblasts PKC-e is not a major regulator of PLD activity.
the length of incubation time (5-60 min) used (Z. Kiss and W. H. Anderson, unpublished work). However, the amount of PKC-e in normal fibroblasts may be nearly sufficient to activate PLD fully in the presence of PMA. Clearly, to prove definitely the specific role of PKC-e in the regulation of phospholipid hydrolysis, it is necessary to demonstrate that selective downregulation of this isoenzyme prevents activation of PLD by PMA.
In fibroblasts and several other cell types, activated PLD hydrolyses both PtdCho and PtdEtn with similar efficiencies [13] [14] [15] [16] [17] [18] [19] . Interestingly, transformation of fibroblasts by v-raf or Ha-ras was found to alter PMA-stimulated hydrolysis of both PtdEtn and PtdCho [14] . This gave the idea that carcinogens may also alter phorbol ester regulation of PLD, perhaps through inducing selective changes in the PKC isoenzyme pattern.
The C3H/lOTl/2 embryonic fibroblast line is a well established cellular model for the study of chemical carcinogenesis [20] [21] [22] [10, 24] ; the incubation medium also contained carcinogen at the appropriate concentration. Fractionation ofcholine and ethanolamine metabolites was performed on Dowex-50 W (HI)-packed columns (Bio-Rad Econo-columns; 1 ml bed volume) with minor modifications of the procedure described by Cook and Wakelam [26] . The initial flow-through (4.5 ml), along with a following 3.5 ml or 5 ml water wash, contained glycerophosphoethanolamine or glycerophosphocholine respectively. Ethanolamine phosphate and choline phosphate were eluted by 15 ml and 20 ml of water, respectively. Finally, ethanolamine and choline were eluted by 12 ml and 20 ml of 1 M HCI, respectively. The metabolites of ['4C]ethanolamine and [14C]choline were further identified by t.l.c. [13] . Phospholipids were separated as described previously [27] .
Determination ot the formation of phosphatidylethanol (PtdEtOH) In fibroblasts This was performed with [14C]palmitic acid-labelled fibroblasts as previously described [25] . from the cytoplasmic (Figure 1 , lane 5) to the membrane fraction ( Figure 1, lane 6 ). DMBA did not appear to interfere with PMAinduced membrane translocation of the small amount of PKC-e which remained in the fibroblasts after carcinogen treatment ( Figure 1, lanes 7, 8) . We still should note here that, with each PKC-isoenzyme-specific antibody examined here (see also Figure   identity of this clearly non-specific band is at present unknown;
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we only determined that it derives from the preparation of streptavidin-alkaline phosphate conjugate.
In fibroblast cultures present in the slow growth phase (90-100 % confluent), PKC-e was still predominantly present in the cytosolic fraction (Figure 2a, lane 1) , but a significant portion of enzyme molecules was also present in the membrane fraction (Figure 2a, lane 2) . In contrast with rapidly growing fibroblasts, in these fibroblasts PKC-e was often (but not always; see Figure  3 ) represented by two, slower and faster moving, bands. Only the upper band could be labelled with [32P]P (results not shown). When fibroblasts were treated with 0.5 ,tg/ml DMBA for only 4 h, there was less than 25 % decrease in the cellular content of PKC-e (results not shown). However, treatment of fibroblasts for 12 h with 0.05 (Figure 2a, lanes 3, 4) , 0.1 (Figure 2a, lanes 5, 6) or 0.5 jug/ml DMBA (Figure 2a, lanes 7, 8) resulted, in each case, in greater than 60 % decreases in the cellular content of PKC-c. It is important to note that at this time point PKC-c was still detectable, even in the presence of the highest concentration of DMBA. Treatment of fibroblasts with 100 nM PMA for 10 min specifically enhanced the membrane content ofthe slower moving (phosphorylated) form of PKC-e (Figure 2b, lanes 1, 2) . Treatment of cells with DMBA for 12 h before the addition of PMA did not interfere with PMA-induced translocation of remaining PKC-e (Figure 2b, lanes 3-8) .
When fibroblasts were treated with DMBA for 24 h and then harvested in the near-confluent state, we observed complete elimination of PKC-e by the highest (0.5 jig/ml) concentration of carcinogen ( Figure 2c, lanes 7, 8) . Again, lower concentrations of carcinogens failed to modify the effect of PMA on membrane translocation of the remaining PKC-e molecules (Figure 2d,  lanes 3-6) .
When near-confluent fibroblasts were treated with 0.5 ,tg/ml B[a]P for 24 h, cellular PKC-e was decreased below the detection limit (Figure 3) . At a lower dose (0.1 ,ag/ml) of B[a]P, which is sub-optimal with respect to inducing cell transformation [20] Of the nine other PKC isoenzymes which have been described in various cell types so far [9] , in these fibroblasts we have detected the a, a and C isoenzymes. In control (-50-60% confluent) fibroblasts, about 90 % of PKC-a was present in the cytosolic fraction (Figure 4a, lanes 1, 2) . Chronic (24 h) treatment of fibroblasts with 0.5 ,tg/ml DMBA failed to cause any change in the cellular content or distribution of this enzyme (Figure 4a,  lanes 3, 4) . A short (10 min) treatment of control fibroblasts with PMA (100 nM) resulted in both partial down-regulation (about 30 40 % of total cellular pool) and membrane translocation of the remaining PKC-a molecules (Figure 4a, lanes 5, 6) . Pretreatment of fibroblasts with DMBA consistently caused an apparent increase in PMA-induced translocation of PKC-a (-1.8-fold; n = 4) (Figure 4a, lanes 7, 8) . Presumably, carcinogen treatment decreased the ability of membranes to down-regulate translocated PKC-cx.
In control fibroblasts, the major portion of PKC4 was also present in the cytosolic fraction, and this pattern of distribution was not altered by DMBA treatment (Figure 4b (Figure 4b, lanes 7, 8) . Treat- (Figure 4c ).
In view of the observation that carcinogens more completely down-regulated PKC-e in the slowly growing fibroblasts, it was decided to examine the effects of DMBA on the a-, d-and y-PKC isoenzymes in near-confluent fibroblast cultures. Treatment of these (90-100% confluent) cultures with 0.5 ,ug/ml DMBA for 24 h also failed to decrease significantly the cellular content of these PKC isoenzymes (results not shown).
Effects of carcinogens and PMA on PLD-mediated hydrolysis of PtdEtn and PtdCho The above observations, that in the slow-(or no-) growth phase carcinogens can selectively down-regulate PKC-e, made carcinogen-treated fibroblasts an ideal choice to explore the role of PKC-e in the regulation of PLD activity. Because the hydrolysis of PtdEtn and PtdCho is oppositely affected by cell transformation [14] , it appeared more informative to examine first the effects of carcinogens on the hydrolysis of individual phospho- (Figure 5b) . However, carcinogens failed to change appreciably the fold stimulatory effects of PMA on the formation of [14C]choline ( Figure Sb) . We should note here that, at the conclusion of PLD assay, PKC-e was completely absent from carcinogen-treated fibroblasts, as determined in subsequent experiments (results not shown).
Formation of PtdEtOH appears to be a specific function of PLD. To confirm that PMA-induced phospholipid hydrolysis Since carcinogens down-regulated only PKC-e, and this isoenzyme was considered as a potential regulator of PLD [10, 11] Whether or not these small stimulatory and inhibitory effects of carcinogens are related to the loss of PKC-e remains to be established. Since carcinogens also slightly decreased the effects of sphingosine and staurosporine, agents which are unlikely to act through the stimulation of the regulatory PKC isoenzyme, even the carcinogen-induced small decreases in the effects of PMA and PDGF may be unrelated to down-regulation of PKC-e.
Our finding that PKC-e does not play a major role in the regulation of PLD activity contrasts with the conclusion reached by Pfeilschifter and Huwiler [11] . These authors reported [11] that treatment of rat mesangial cells with PMA for 8 h resulted in full activation of PLD activity, despite complete downregulation of PKC-a and PKC-4. Since under the same condition PKC-c was not down-regulated, Pfeilschifter and Huwiler [11] concluded that this isoenzyme regulates PLD activity. This suggests that in different cell types different PKC isoenzymes may regulate PLD activity. Alternatively, in both cell lines regulation ofPLD by PMA may involve an at present unidentified phorbol-ester-binding protein. Although further experiments are required to distinguish between these possibilities, we also observed that 15-fold overexpression of PKC-e in NIH 3T3 fibroblasts [12] enhanced the stimulatory effects of 5-40 nM PMA on PLD activity about 1.5-fold (Z. Kiss and W. H. Anderson, unpublished work). Although this does not necessarily mean that PKC-c is a direct regulator of PLD, at present we cannot exclude the possibility that a minor pathway of PLD regulation indeed involves PKC-e.
These experiments are not suitable to determine the possible regulatory role of the other PKC isoenzymes present in fibroblasts. PKC-a is a major isoenzyme in these cells, and therefore it may not be the rate-limiting factor in activating PLD. Therefore, the small potentiating effects of carcinogens on PMAinduced membrane translocation of PKC-a may not necessarily lead to increased activity Qf PLD, even if this isoenzyme is the major regulator of phospholipid hydrolysis. The same consideration may be applicable concerning the possible regulatory role of PKC-8. On the basis that PKC-C does not respond to PMA in any conventional way [28] [29] [30] [31] , at present we do not consider this isoenzyme as a possible regulator of PLD.
The mechanism by which carcinogens decrease the cellular content of PKC-e is at present unknown. In principle, inhibition of synthesis of PKC-e or stimulation of its degradation are the most likely mechanisms that may be involved in this action of carcinogen. Examination of both possible mechanisms is at present underway in our laboratory.
In other studies, PKC-e was shown to assume oncogenic properties when overexpressed in fibroblasts [32, 33] . This would suggest that up-regulation of this enzyme may be required for neoplastic transformation. However, the present finding that carcinogens down-regulate PKC-e appears to be incompatible with this hypothesis. In fact, it is quite possible that chemical carcinogenesis involves down-regulation ofPKC-e. Clearly, more work is required to clarify the role, if any, of PKC-e in carcinogenesis.
In summary, carcinogens were shown to down-regulate PKCc specifically. The role of this phenomenon in chemical carcinogenesis remains to be established. Down-regulation of PKC-e led only to a relatively small decrease (PtdEtn hydrolysis) or no
